Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).
Kyle SmootHoria MargineanTiffany Gervasi-FollmarChiayi ChenPavle RepovicStanley CohanPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)
NCT03157830.
Keyphrases